drugset / Trial / NCT04978038
Fourth Dose of mRNA COVID-19 Vaccine in Residents of LTCFs
RandomizedParallel-groupTriple-blindPrevention
Summary
This study is a multi-centre, blinded, randomized controlled trial. LTCF residents ≥ 65 years who have received three doses of mRNA vaccine will be randomized to vaccination with a fourth dose of Pfizer-BioNtech mRNA- COVID-19 vaccine or to vaccination with a control (Prevnar-13 vaccine).
Timeline
- Start
- 2022-08-01
- Primary completion
- 2022-11-15
- Completion
- 2022-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Prevnar 13 | Vaccine | 0.5 ml | Intramuscular |
| Subject | mRNA COVID-19 | Messenger RNA (mRNA) | 0.3 ml | Intramuscular |